|
|
Article: Bristol-Myers Squibb to Share Diabetes Drug Rights with Merck.
- Article from:
- Knight Ridder/Tribune Business News
- Article date:
- April 29, 2004
CopyrightCOPYRIGHT 2004 Knight-Ridder/Tribune Business News. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
By Lewis Krauskopf, The Record, Hackensack, N.J. Knight Ridder/Tribune Business News
Apr. 29--Bristol-Myers Squibb Co. said Wednesday it agreed to share rights to its promising diabetes drug with Merck & Co. for as much as $375 million, reflecting what CEO Peter Dolan described as a strategic shift.
The deal, which came as Bristol announced a 22 percent rise in first-quarter profits, means the two New Jersey companies will now jointly develop the clinical and marketing plans for Muraglitazar, now in the final phase of study, and share future costs. Both companies would promote the drug.
In recent years, Bristol has raked in money from ...